Elanco Animal Health Incorporated Restructuring Costs and Asset Impairment Charges
Elanco Animal Health Incorporated (ELAN) reported Restructuring Costs and Asset Impairment Charges of $9.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2026-08-05
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for the quarter ending 2026-06-30 was $9.00M, a 800.00% increase year-over-year.
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for the quarter ending 2026-03-31 was $16.00M, a 77.78% increase year-over-year.
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for the quarter ending 2025-12-31 was $202.00M, a 2785.71% increase year-over-year.
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for the quarter ending 2025-09-30 was $25.00M, a 47.06% increase year-over-year.
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for fiscal 2025 was $237.00M, a 58.00% increase from fiscal 2024.
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for fiscal 2024 was $150.00M, a 18.11% increase from fiscal 2023.
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for fiscal 2023 was $127.00M, a 30.60% decline from fiscal 2022.
- Elanco Animal Health Incorporated restructuring costs and asset impairment charges for fiscal 2022 was $183.00M, a 71.14% decline from fiscal 2021.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.00M 10-Q · filed 2026-08-05 | $25.00M 10-Q · filed 2026-08-05 | $227.00M derived: sum of 3 quarters · filed 2026-08-05 | $252.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $16.00M 10-Q · filed 2026-05-06 | $218.00M derived: sum of 2 quarters · filed 2026-05-06 | $243.00M derived: sum of 3 quarters · filed 2026-05-06 | $244.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $202.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $227.00M derived: sum of 2 quarters · filed 2026-02-24 | $228.00M derived: sum of 3 quarters · filed 2026-08-05 | $237.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $25.00M 10-Q · filed 2025-11-05 | $26.00M derived: sum of 2 quarters · filed 2026-08-05 | $35.00M 10-Q · filed 2025-11-05 | $42.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-05 | $10.00M 10-Q · filed 2026-08-05 | $17.00M derived: sum of 3 quarters · filed 2026-08-05 | $34.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $9.00M 10-Q · filed 2026-05-06 | $16.00M derived: sum of 2 quarters · filed 2026-05-06 | $33.00M derived: sum of 3 quarters · filed 2026-05-06 | $113.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $24.00M derived: sum of 2 quarters · filed 2026-02-24 | $104.00M derived: sum of 3 quarters · filed 2026-02-24 | $150.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $17.00M 10-Q · filed 2025-11-05 | $97.00M derived: sum of 2 quarters · filed 2025-11-05 | $143.00M 10-Q · filed 2025-11-05 | $179.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $80.00M 10-Q · filed 2025-08-07 | $126.00M 10-Q · filed 2025-08-07 | $162.00M derived: sum of 3 quarters · filed 2026-02-24 | $178.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $46.00M 10-Q · filed 2025-05-07 | $82.00M derived: sum of 2 quarters · filed 2026-02-24 | $98.00M derived: sum of 3 quarters · filed 2026-02-24 | $133.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $52.00M derived: sum of 2 quarters · filed 2026-02-24 | $87.00M derived: sum of 3 quarters · filed 2026-02-24 | $127.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $16.00M 10-Q · filed 2024-11-07 | $51.00M derived: sum of 2 quarters · filed 2024-11-07 | $91.00M 10-Q · filed 2024-11-07 | $122.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $35.00M 10-Q · filed 2024-08-08 | $75.00M 10-Q · filed 2024-08-08 | $106.00M derived: sum of 3 quarters · filed 2025-02-25 | $132.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $40.00M 10-Q · filed 2024-05-08 | $71.00M derived: sum of 2 quarters · filed 2025-02-25 | $97.00M derived: sum of 3 quarters · filed 2025-02-25 | |
| 2022-12-31 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $57.00M derived: sum of 2 quarters · filed 2025-02-25 | $183.00M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $26.00M 10-Q · filed 2023-11-07 | $152.00M 10-Q · filed 2023-11-07 | ||
| 2021-12-31 | $634.00M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |